Department of Pharmacy, Kumamoto University Hospital, Kumamoto, Japan.
Departments of Neurosurgery, Kurume University School of Medicine, Fukuoka, Japan.
Pharmacol Res Perspect. 2021 Apr;9(2):e00719. doi: 10.1002/prp2.719.
Intracranial pressure (ICP) has to be maintained quite constant, because increased ICP caused by cerebrovascular disease and head trauma is fatal. Although controlling ICP is clinically critical, only few therapeutic methods are currently available. Barbiturates, a group of sedative-hypnotic drugs, are recognized as secondary treatment for controlling ICP. We proposed a novel "step-down infusion" method, administrating barbiturate (thiamylal) after different time point from the start of treatment under normothermia, at doses of 3.0 (0-24 h), 2.0 (24-48 h), 1.5 (48-72 h), and 1.0 mg/kg/h (72-96 h), and evaluated its safety and effectiveness in clinical. In 22 patients with severe traumatic brain injury or severe cerebrovascular disease (Glasgow coma scale ≤8), thiamylal concentrations and ICP were monitored. The step-down infusion method under normothermia maintained stable thiamylal concentrations (<26.1 µg/ml) without any abnormal accumulation/elevation, and could successfully keep ICP <20 mmHg (targeted management value: ICP <20 mmHg) in all patients. Moreover the mean value of cerebral perfusion pressure (CPP) was also maintained over 65 mmHg during all time course (targeted management value: CPP >65 mmHg), and no threatening changes in serum potassium or any hemodynamic instability were observed. Our novel "step-down infusion" method under normothermia enabled to maintain stable, safe thiamylal concentrations to ensure both ICP reduction and CPP maintenance without any serious side effects, may provide a novel and clinically effective treatment option for patients with increased ICP.
颅内压(ICP)必须保持相当恒定,因为脑血管病和头部创伤引起的 ICP 升高是致命的。尽管控制 ICP 在临床上至关重要,但目前只有少数治疗方法可用。巴比妥类药物是一组镇静催眠药物,被认为是控制 ICP 的二线治疗药物。我们提出了一种新的“逐步下调输注”方法,在正常体温下,从治疗开始后的不同时间点开始给予巴比妥类药物(硫喷妥钠),剂量分别为 3.0(0-24 小时)、2.0(24-48 小时)、1.5(48-72 小时)和 1.0mg/kg/h(72-96 小时),并在临床中评估其安全性和有效性。在 22 例严重创伤性脑损伤或严重脑血管病患者(格拉斯哥昏迷量表≤8)中,监测硫喷妥钠浓度和 ICP。正常体温下的逐步下调输注方法维持稳定的硫喷妥钠浓度(<26.1µg/ml),没有任何异常的蓄积/升高,并能成功地使所有患者的 ICP<20mmHg(目标管理值:ICP<20mmHg)。此外,在整个时间过程中,平均脑灌注压(CPP)也维持在 65mmHg 以上(目标管理值:CPP>65mmHg),没有观察到血清钾或任何血流动力学不稳定的威胁性变化。我们的新方法在正常体温下进行逐步下调输注,能够维持稳定、安全的硫喷妥钠浓度,确保 ICP 降低和 CPP 维持,没有任何严重的副作用,可能为 ICP 升高的患者提供一种新的、有效的临床治疗选择。